MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTC: AOLS), today announced that it has been invited to deliver an oral presentation on AEOL 10150, the Company's novel, broad-spectrum catalytic antioxidant compound that reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure in development for use in oncology, where it will be used in combination with radiation therapy, and as a medical countermeasure against the pulmonary sub-syndrome of acute radiation syndrome (“Pulmonary Acute Radiation Syndrome” or “Lung-ARS”) as well as the gastrointestinal sub-syndrome of acute radiation syndrome (“GI-ARS”), both caused by exposure to high levels of radiation due to a radiological or nuclear event, at the Biomedical Advanced Research and Development Authority (BARDA) Industry Day.
